SCHEMBL836065

SCHEMBL836065

COc1ccc2c(c1)c(Sc1ccc(C)cc1)cc(=O)n2C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
NPSR1 Q6W5P4 3/20 0.45
RXFP1 Q9HBX9 3/20 0.44
PRNP P04156 1/20 0.42
AKR1B1 P15121 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
APAF1 O14727 1/20 0.40
PABPC1 P11940 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829084 0.89 MAPT (0.46) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL836066 0.86 RXFP1 (0.48) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL835189 0.83 KDM4E (0.51) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL835001 0.82 RXFP1 (0.44) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL14300144 0.81 RXFP1 (0.58) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL835232 0.80 KDM4E (0.44) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL14302623 0.79 LMNA (0.43) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL836059 0.79 RHEB (0.50) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL835287 0.79 RXFP1 (0.43) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL829660 0.79 MEN1 (0.43) MAPTALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A MAPT 2002/4885ALDH1A1 1179/4885KMT2A 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.